Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
NCT: NCT04592445 · RECRUITING
Brief Summary
The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.
Frequently Asked Questions
What is Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF?
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF is a clinical trial registered under NCT04592445. Current status: RECRUITING.
What is the status of NCT04592445?
The current status of NCT04592445 (Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF) is: RECRUITING.
When did Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF start?
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF started on 2020-12-18.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.